SCHEMBL4355235

SCHEMBL4355235

Cc1ccc(C=O)c(-c2ccc3ncnc(NCCC(C)C)c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
CYP1A2 P05177 12/20 0.48
CYP3A4 P08684 12/20 0.48
CLK4 Q9HAZ1 11/20 0.48
ALDH1A1 P00352 11/20 0.48
CYP2D6 P10635 10/20 0.48
TSHR P16473 8/20 0.48
HSD17B10 Q99714 8/20 0.48
CYP2C19 P33261 7/20 0.48
USP2 O75604 4/20 0.48
HIF1A Q16665 2/20 0.48
MAPK1 P28482 4/20 0.47
ALOX15 P16050 3/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 3/20 0.46
MAP4K4 O95819 1/20 0.44
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351900 0.88 CYP1A2 (0.53) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4362086 0.86 CLK4 (0.48) L3MBTL1CYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL4353347 0.86 MEN1 (0.49) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4351406 0.84 CLK4 (0.48) L3MBTL1CYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL4363808 0.83 CLK4 (0.48) L3MBTL1CYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL4358711 0.82 MAP4K4 (0.50) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4363862 0.80 MAP4K4 (0.55) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4356003 0.79 MAP4K4 (0.45) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4361933 0.79 CYP1A2 (0.51) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL4351387 0.79 LMNA (0.47) L3MBTL1CYP1A2CYP3A4CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 L3MBTL1 1143/4885CYP1A2 1131/4885CYP3A4 256/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 L3MBTL1 1143/4885CYP1A2 1131/4885CYP3A4 256/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 L3MBTL1 2036/4885CYP1A2 1129/4885CYP3A4 274/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 L3MBTL1 2604/4885CYP1A2 1078/4885CYP3A4 271/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 L3MBTL1 2604/4885CYP1A2 1078/4885CYP3A4 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.